# Delayed presentation of a retained colonic segment in a child with intestinal failure on teduglutide

## TL;DR

A child with intestinal failure on teduglutide treatment had a long-retained colon segment become clinically significant.

## Contribution

Reports a novel case of delayed clinical significance of a retained colonic segment in a child on teduglutide.

## Key findings

- A retained colonic segment from infancy became clinically relevant after a decade.
- Teduglutide treatment may have influenced the delayed presentation of the retained segment.
- The case highlights potential long-term effects of surgical interventions in early life.

## Abstract

Teduglutide is a glucagon‐like peptide 2 (GLP‐2) analogue that was approved by the United States Food and Drug Administration for the treatment of pediatric (>1 year) intestinal failure due to short bowel syndrome in 2019. GLP‐2 analogues promote rapid intestinal adaptation, increasing the absorptive capacity of residual intestine after surgical resection to aid the achievement of enteral autonomy or reduce parenteral nutrition requirements. Despite relatively few reported side effects, there is a theoretical risk of proliferative complications. Here we present an intriguing case of a pediatric patient found to have a decade‐long retained, discontinuous segment of colon from a surgical procedure performed in infancy, which became clinically significant after a period of treatment with teduglutide.